Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024 -- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio’s long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at...

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on...

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating...

Assembly Biosciences Announces Effective Date of Reverse Stock Split – Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc....